<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The most serious long-term complications of anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> therapy are <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Parameters which might allow an estimation of the individual risk to develop a therapy-induced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> are urgently needed </plain></SENT>
<SENT sid="2" pm="."><plain>We examined whether the genotypes of the <z:chebi fb="0" ids="16856">glutathione</z:chebi> S-transferases (GST) M1 and T1, which metabolize various <z:chebi fb="0" ids="35610">cytostatic</z:chebi> drugs, as well as reactive oxygen species, influence the risk for secondary <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In a retrospective study, we analyzed peripheral blood lymphocyte or bone marrow DNA samples from 213 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 128 with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) 44 of whom suffered from therapy-associated <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The control group consisted of 239 healthy individuals with comparable composition as to race and sex </plain></SENT>
<SENT sid="5" pm="."><plain>GSTM1 and GSTT1 were analyzed by multiplex PCR </plain></SENT>
<SENT sid="6" pm="."><plain>Comparison between patients and control group revealed a significant (P=0.0003) overrepresentation of combined deletions of both GSTM1 and GSTT1 (double null genotype) in the group of patients with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> secondary to chemo- and/or radiotherapy of a <z:mp ids='MP_0002038'>carcinoma</z:mp> of the breast </plain></SENT>
<SENT sid="7" pm="."><plain>In this group, 55% of the patients displayed the double null genotype as compared with 8.8% in the control group </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that patients with <z:mp ids='MP_0002038'>carcinoma</z:mp> of the breast and <z:hpo ids='HP_0000005'>inheritance</z:hpo> of a combined gene deletion of GSTM1 and GSTT1 might bear an increased risk to develop a secondary therapy-induced hematologic <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>An insufficient detoxification of <z:chebi fb="0" ids="35610">cytostatic</z:chebi> drugs such as <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> is suggested to represent the underlying pathomechanism </plain></SENT>
</text></document>